126 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release
6-K
EX-99.9
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Agreement also included, amongst other things, a commitment to make a proposal to an extraordinary shareholders’ meeting of the Company to renew
6-K
EX-99.3
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
on 14 July 2019, as amended from time to time (the “Subscription Agreement”), which included a commitment to make a proposal to the general meeting … a commitment to make a proposal to the shareholders’ meeting to authorize the Board of Directors to increase the share capital of the Company in one
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
report Our Sustainability Commitment – Forward, Sustainably 82 Our Ambition 83 Our Sustainability Governance 84 Our Double Materiality Assessment 84 … future challenges.
Sustainability report Our commitment to society: Forward, Sustainably Pioneering science to transform patient outcomes
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
. The Remuneration Committee believes this demonstrates a clear commitment to better align with market practice and views from shareholders gathered during our … of the Executive Committee members with those of shareholders and demonstrate their commitment, the existing share ownership requirements will be doubled
6-K
EX-99.5
1wanwpv2pindf6 p9u
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
oi2tsz
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.4
npae5ku238eh0jigvd
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
wxryp08857yoj 7jlsm
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
7xwvqx4 q6fi63b78vhb
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
9jh89yg
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
08d8hliyjld43glkat
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
bis1i0
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
eja5wrf36607keduxj
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
zbs9oq
12 Dec 23
Current report (foreign)
6:00am
S-8
EX-4.1
zk7l owumu10wz
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
6eyjskutt2o rnhs
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
c1dr wdh2x65h9j
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
EX-99.1
aed 2fcmie
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm